文献速递头颈部肿瘤放疗姑息放疗与转移瘤

老年头颈癌放疗:标准治疗在老年人群中的价值

Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?
PubMed 文献 · Radiat Oncol · 2020-02-04

2年OS、PFS、LRC分别为56.9%、44.9%、75.5%。65-74岁根治性治疗加同步化疗较单纯放疗改善OS,≥75岁无获益;低体能状态与吸烟为OS独立不良预后因素。

要点

  • 老年头颈鳞癌放疗可行,2年LRC达75.5%而OS仅56.9%。
  • 65-74岁根治性同步化疗改善OS,≥75岁未见获益。
  • 低体能状态(HR=2.584)与吸烟(HR=1.960)独立预测OS下降。

核心结论

  • 放疗是老年头颈鳞癌患者的可行治疗方式,但同步化疗在老年人群需审慎讨论。

研究设计与样本

  • 其中根治性治疗166例、辅助治疗80例,按CTCAE v5.0量化急性和晚期毒性。

主要发现

  • 全组2年OS、PFS、LRC分别为56.9%、44.9%、75.5%。
  • 65-74岁与≥75岁患者OS分别为40个月与22个月,PFS分别为23个月与12个月(p<0.05)。
  • 根治性治疗中65-74岁同步化疗较单纯放疗改善OS(p<0.05),≥75岁无获益(p=0.904)。
  • 辅助化放疗在65-74岁见OS优于单纯放疗的趋势(p=0.151)。
  • 多因素分析中低体能状态(HR=2.584,95%CI 1.561-4.274;p<0.001)与吸烟(HR=1.960,95%CI 1.109-3.464,p<0.05)为OS下降的独立预后因素。

临床怎么用

  • 对≥75岁头颈鳞癌患者,根治性同步化疗的获益证据不足,应个体化权衡。
  • 治疗决策需综合评估体能状态与吸烟史,低体能状态者OS风险显著升高。

局限性

  • 为单中心回顾性分析,老年患者在前瞻性临床试验中代表性不足,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Head-and-neck squamous cell carcinoma (HNSCC) is one of the most common malignancies globally, and the number of elderly patients diagnosed with HNSCC is increasing. However, as elderly HNSCC patients are underrepresented in clinical trials, current clinical decision making for this cohort largely lacks clinical evidence. METHODS: Elderly patients (≥65 years) with HNSCC undergoing (chemo)radiotherapy from 2010 to 2018 at Freiburg University Medical Center were assessed for patterns of care, locoregional control (LRC), progression-free (PFS) and overall survival (OS) regarding definitive and adjuvant treatments. Acute and late therapy-associated toxicities were quantified according to CTCAE v5.0. RESULTS: Two hundred forty-six patients were included in this analysis, of whom 166 received definitive and 80 adjuvant treatment. Two-year rates for OS, PFS and LRC were 56.9, 44.9 and 75.5%, respectively. Survival differed significantly between age groups with an OS of 40 and 22 months and a PFS of 23 and 12 months for patients aged 65-74 or ≥ 75 years, respectively (p < 0.05). Concomitant chemotherapy resulted in improved OS in patients aged 65-74 years compared to radiotherapy alone (p < 0.05) for definitive treatments, while patients ≥75 years did not benefit (p = 0.904). For adjuvant chemoradiotherapy, a trend towards superior OS rates was observed for patients aged 65-74 years (p = 0.151). Low performance status (HR = 2.584, 95% CI 1.561-4.274; p < 0.001) and smoking (HR = 1.960, 95% CI 1.109-3.464, p < 0.05) were the strongest independent prognostic factor in the multivariate analysis for decreased OS. One hundred thirty-eight patients (56.1%) experienced acute grade 3/4 and 45 patients (19.9%) chronic grade 3 toxicities. CONCLUSION: Radiotherapy is a feasible treatment modality for elderly HNSCC patients. The relatively low OS compared to high LRC may reflect age and comorbidities. Concomitant chemotherapy should be critically discussed in elderly HNSCC patients.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Haehl E, Rühle A, David H, et al. Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly? Radiat Oncol. 2020. PMID: 32019576. doi:10.1186/s13014-020-1481-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。